Cellectis S.A.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cellectis S.A. (Nasdaq: CLLS; Euronext Growth: ALCLS) is a clinical-stage biopharmaceutical company focused on gene-edited allogeneic CAR T-cell immunotherapies for cancer using its proprietary TALEN gene-editing technology and PulseAgile electroporation system; core product candidates include lasme-cel (UCART22) for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), eti-cel (UCART20x22) for relapsed/refractory non-Hodgkin lymphoma (r/r NHL), and earlier-stage UCARTs targeting hematologic malignancies such as acute myeloid leukemia; the company pioneered off-the-shelf allogeneic CAR T-cells from healthy donors, enabling scalable, standardized manufacturing distinct from patient-specific autologous therapies. Founded in 1999 and headquartered at 8 Rue de la Croix Jarry in Paris, France, with additional facilities in New York, New York, and Raleigh, North Carolina, Cellectis operates primarily in the United States and Europe, targeting patients with high unmet needs in oncology through clinical trials and strategic manufacturing sites for plasmids, mRNA, viral vectors, and GMP UCART production. Recent developments include positive Phase 1 data for lasme-cel showing 68% overall response rate (83% at recommended Phase 2 dose) and median overall survival of 14.8 months in MRD-negative responders, with pivotal Phase 2 interim analysis expected in Q4 2026 and BLA submission in 2028; encouraging eti-cel results with 86% ORR and 57% complete response rate in r/r NHL, full Phase 1 data due in 2026; a 2023 strategic collaboration and investment with AstraZeneca involving up to $140 million equity and joint R&D for 10 cell/gene therapy programs in oncology, immunology, and rare diseases, yielding $47 million by end-2024; ongoing Servier arbitration decision expected by December 15, 2025; and advancements in non-viral CssDNA templates and TALEB base editors presented at ESGCT 2025.
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Monthly information on share capital and company voting rights
Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
Cellectis Reports Financial Results for the First Quarter 2026
Monthly information on share capital and company voting rights
Cellectis to Report First Quarter Financial Results on May 11, 2026
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la plateforme CAR-T allogénique de Cellectis
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform
Monthly information on share capital and company voting rights
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Monthly information on share capital and company voting rights
Cellectis (NASDAQ:CLLS) Share Price Crosses Below 50-Day Moving Average – What’s Next?